{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ATC|ANTIINFECTIVES FOR SYSTEMIC USE" in comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT01715493: Phase 4 Interventional Completed Chronic Obstructive Pulmonary Disease
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 346
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT03051516: Phase 4 Interventional Terminated High Grade Anal Canal Intraepithelial Neoplasia
(2017)
Source URL:
First approved in 2006
Source:
BLA125126
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT03051516: Phase 4 Interventional Terminated High Grade Anal Canal Intraepithelial Neoplasia
(2017)
Source URL:
First approved in 2006
Source:
BLA125126
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
US Approved Rx
(2001)
First approved in 1986
Source:
DIGIBIND by WELLCOME FOUNDATION LIMITED WELLCOME RESEARCH LABORATORIES
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(1977)
First approved in 1977
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2001)
First approved in 1977
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(1971)
First approved in 1971
Source:
BLA101069
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(1999)
First approved in 1953
Source:
BLA103915
Source URL:
Class:
STRUCTURALLY DIVERSE
